Relative stability and significance of dawsonite and aluminum minerals in geologic carbon sequestration

[1] Computer simulations predict dawsonite, NaAlCO 3 (OH) 2 , will provide l ong -term mineral sequestration of anthropogenic CO 2 whereas dawsonite rarely occurs in nature or in laboratory experiments that emulate a carbon repository. Resolving this discrepancy is important to determining the significance of dawsonite mineralization to the long-term security of geologic carbon sequestration. This study is an equilibrium-based experimental and modeling evaluation of underlying causes for inconsistencies between predicted and observed dawsonite stability. Using established hydrothermal methods, 0.05 molal NaHCO 3 aqueous solution and synthetic dawsonite were reacted for 18.7 days (449.2 hours) at 50°C, 20 MPa. Temperature was increased to 75°C and the experiment continued for an additional 12.3 days (295.1 hours). Incongruent dissolution yielded a dawsonite-gibbsite-nordstrandite assemblage. Geochemical simulations using Geochemist's Workbench and the resident database thermo.com.V8.R6 + incorrectly predicted a dawsonite-diaspore assemblage and underestimated dissolved aluminum by roughly 100 times. Higher aqueous aluminum concentrations in the experiment suggest that dawsonite or diaspore is less stable than predicted. Simulations employing an alternate database, thermo.dat, correctly predict dawsonite and dawsonitegibbsite assemblages at 50 and 75°C, respectively, although dissolved aluminum concentrations are still two to three times lower than experimentally measured values. Correctly reproducing dawsonite solubility in standard geochemical simulations requires an as yet undeveloped internally consistent thermodynamic database among dawsonite, gibbsite, boehmite, diaspore, aqueous aluminum complexes and other Al-phases such as albite and kaolinite. These discrepancies question the ability of performance assessment models to correctly predict dawsonite mineralization in a sequestration site. Citation: Kaszuba, J. P., H. S. Viswanathan, and J. W. Carey (2011), Relative stability and significance of dawsonite and aluminum minerals in geologic carbon sequestration, Geophys. Res. Lett., 38, L08404

Constraining the fluid history of a CO2 -H2 S reservoir: insights from stable isotopes, REE and fluid inclusion microthermometry

Reservoirs that host CO2‐H2S‐bearing gases provide a key insight into crustal redox reactions such as thermochemical sulfate reduction (TSR). Despite this, there remains a poor understanding of the extent, duration, and the factors limiting this process on a reservoir scale. Here we show how a combination of petrography, fluid inclusion, rare earth element (REE), and carbon (δ13C), oxygen (δ18O), and sulfur (δ34S) stable isotope data can disentangle the fluid history of the world's largest CO2 accumulation, the LaBarge Field in Wyoming, USA. The carbonate‐hosted LaBarge Field was charged with oil around 80 Ma ago, which together with nodular anhydrite represent the reactants for TSR. The nodules exhibit two distinct trends of evolution in δ13C with both δ34S and δ18O that may be coupled to two different processes. The first trend was interpreted to reflect the coupled dissolution of anhydrite and reduction to elemental sulfur and the oxidation of organic compounds and associated precipitation of calcite during TSR. In contrast, the second trend was interpreted to be the result of the hydrothermal CO2 influx after the cessation of TSR. In addition, mass balance calculations were performed to estimate an approximate TSR reaction duration of 80 ka and to identify the availability of organic compounds as the limiting factor of the TSR process. Such an approach provides a tool for the prediction of TSR occurrence elsewhere and advancing our understanding of crustal fluid interactions

Structural Analysis of Prolyl Oligopeptidases Using Molecular Docking and Dynamics: Insights into Conformational Changes and Ligand Binding

Prolyl oligopeptidase (POP) is considered as an important pharmaceutical target for the treatment of numerous diseases. Despite enormous studies on various aspects of POPs structure and function still some of the questions are intriguing like conformational dynamics of the protein and interplay between ligand entry/egress. Here, we have used molecular modeling and docking based approaches to unravel questions like differences in ligand binding affinities in three POP species (porcine, human and A. thaliana). Despite high sequence and structural similarity, they possess different affinities for the ligands. Interestingly, human POP was found to be more specific, selective and incapable of binding to a few planar ligands which showed extrapolation of porcine POP in human context is more complicated. Possible routes for substrate entry and product egress were also investigated by detailed analyses of molecular dynamics (MD) simulations for the three proteins. Trajectory analysis of bound and unbound forms of three species showed differences in conformational dynamics, especially variations in β-propeller pore size, which was found to be hidden by five lysine residues present on blades one and seven. During simulation, β-propeller pore size was increased by ∼2 Å in porcine ligand-bound form which might act as a passage for smaller product movement as free energy barrier was reduced, while there were no significant changes in human and A. thaliana POPs. We also suggest that these differences in pore size could lead to fundamental differences in mode of product egress among three species. This analysis also showed some functionally important residues which can be used further for in vitro mutagenesis and inhibitor design. This study can help us in better understanding of the etiology of POPs in several neurodegenerative diseases

The Integrin Receptor in Biologically Relevant Bilayers: Insights from Molecular Dynamics Simulations

Integrins are heterodimeric (αβ) cell surface receptors that are potential therapeutic targets for a number of diseases. Despite the existence of structural data for all parts of integrins, the structure of the complete integrin receptor is still not available. We have used available structural data to construct a model of the complete integrin receptor in complex with talin F2–F3 domain. It has been shown that the interactions of integrins with their lipid environment are crucial for their function but details of the integrin/lipid interactions remain elusive. In this study an integrin/talin complex was inserted in biologically relevant bilayers that resemble the cell plasma membrane containing zwitterionic and charged phospholipids, cholesterol and sphingolipids to study the dynamics of the integrin receptor and its effect on bilayer structure and dynamics. The results of this study demonstrate the dynamic nature of the integrin receptor and suggest that the presence of the integrin receptor alters the lipid organization between the two leaflets of the bilayer. In particular, our results suggest elevated density of cholesterol and of phosphatidylserine lipids around the integrin/talin complex and a slowing down of lipids in an annulus of ~30 Å around the protein due to interactions between the lipids and the integrin/talin F2–F3 complex. This may in part regulate the interactions of integrins with other related proteins or integrin clustering thus facilitating signal transduction across cell membranes

Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes

Objectives: ANCA-associated vasculitis (AAV) can affect all age groups. We aimed to show that differences in disease presentation and 6 month outcome between younger- A nd older-onset patients are still incompletely understood. Methods: We included patients enrolled in the Diagnostic and Classification Criteria for Primary Systemic Vasculitis (DCVAS) study between October 2010 and January 2017 with a diagnosis of AAV. We divided the population according to age at diagnosis: <65 years or ≥65 years. We adjusted associations for the type of AAV and the type of ANCA (anti-MPO, anti-PR3 or negative). Results: A total of 1338 patients with AAV were included: 66% had disease onset at <65 years of age [female 50%; mean age 48.4 years (s.d. 12.6)] and 34% had disease onset at ≥65 years [female 54%; mean age 73.6 years (s.d. 6)]. ANCA (MPO) positivity was more frequent in the older group (48% vs 27%; P = 0.001). Younger patients had higher rates of musculoskeletal, cutaneous and ENT manifestations compared with older patients. Systemic, neurologic,cardiovascular involvement and worsening renal function were more frequent in the older-onset group. Damage accrual, measured with the Vasculitis Damage Index (VDI), was significantly higher in older patients, 12% of whom had a 6 month VDI ≥5, compared with 7% of younger patients (P = 0.01). Older age was an independent risk factor for early death within 6 months from diagnosis [hazard ratio 2.06 (95% CI 1.07, 3.97); P = 0.03]. Conclusion: Within 6 months of diagnosis of AAV, patients >65 years of age display a different pattern of organ involvement and an increased risk of significant damage and mortality compared with younger patients

Effect of reducing groundwater on the retardation of redox-sensitive radionuclides

Laboratory batch sorption experiments were used to investigate variations in the retardation behavior of redox-sensitive radionuclides. Water-rock compositions were designed to simulate subsurface conditions at the Nevada Test Site (NTS), where a suite of radionuclides were deposited as a result of underground nuclear testing. Experimental redox conditions were controlled by varying the oxygen content inside an enclosed glove box and by adding reductants into the testing solutions

Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis

BACKGROUND Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment of moderate-to-severe psoriasis. We report the 60-week data from the UNCOVER-2 and UNCOVER-3 trials, as well as 12-week and 60-week data from a third phase 3 trial, UNCOVER-1. METHODS We randomly assigned 1296 patients in the UNCOVER-1 trial, 1224 patients in the UNCOVER-2 trial, and 1346 patients in the UNCOVER-3 trial to receive subcutaneous injections of placebo (placebo group), 80 mg of ixekizumab every 2 weeks after a starting dose of 160 mg (2-wk dosing group), or 80 mg of ixekizumab every 4 weeks after a starting dose of 160 mg (4-wk dosing group). Additional cohorts in the UNCOVER-2 and UNCOVER-3 trials were randomly assigned to receive 50 mg of etanercept twice weekly. At week 12 in the UNCOVER-3 trial, the patients entered a long-term extension period during which they received 80 mg of ixekizumab every 4 weeks through week 60; at week 12 in the UNCOVER-1 and UNCOVER-2 trials, the patients who had a response to ixekizumab (defined as a static Physicians Global Assessment [sPGA] score of 0 [clear] or 1 [minimal psoriasis]) were randomly reassigned to receive placebo, 80 mg of ixekizumab every 4 weeks, or 80 mg of ixekizumab every 12 weeks through week 60. Coprimary end points were the percentage of patients who had a score on the sPGA of 0 or 1 and a 75% or greater reduction from baseline in Psoriasis Area and Severity Index (PASI 75) at week 12. RESULTS In the UNCOVER-1 trial, at week 12, the patients had better responses to ixekizumab than to placebo; in the 2-wk dosing group, 81.8% had an sPGA score of 0 or 1 and 89.1% had a PASI 75 response; in the 4-wk dosing group, the respective rates were 76.4% and 82.6%; and in the placebo group, the rates were 3.2% and 3.9% (P<0.001 for all comparisons of ixekizumab with placebo). In the UNCOVER-1 and UNCOVER-2 trials, among the patients who were randomly reassigned at week 12 to receive 80 mg of ixekizumab every 4 weeks, 80 mg of ixekizumab every 12 weeks, or placebo, an sPGA score of 0 or 1 was maintained by 73.8%, 39.0%, and 7.0% of the patients, respectively. Patients in the UNCOVER-3 trial received continuous treatment of ixekizumab from weeks 0 through 60, and at week 60, at least 73% had an sPGA score of 0 or 1 and at least 80% had a PASI 75 response. Adverse events reported during ixekizumab use included neutropenia, candidal infections, and inflammatory bowel disease. CONCLUSIONS In three phase 3 trials involving patients with psoriasis, ixekizumab was effective through 60 weeks of treatment. As with any treatment, the benefits need to be weighed against the risks of adverse events. The efficacy and safety of ixekizumab beyond 60 weeks of treatment are not yet known